Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

9788	Companies
196128	Keywords
127163	Articles
104293	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 09/16/2025 at 07:05, 4 months 17 days ago

Newron Pharmaceuticals Unveils H1 2025 Results and Strategic Advancements

Strategic Partnerships Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment
PRESS RELEASE

published on 09/16/2025 at 07:00, 4 months 17 days ago

Newron presents H1 2025 results and provides business update
Newron Pharmaceuticals S.p.A. presents H1 2025 financial results and business update, focusing on evenamide therapy for treatment-resistant schizophrenia patients and strategic partnerships

Business Update Newron Pharmaceuticals Schizophrenia Treatment H1 2025 Results Evenamide Therapy
BRIEF

published on 09/05/2025 at 07:05, 4 months 28 days ago

Newron Pharmaceuticals to Reveal Evenamide Insights at 2025 WCBP

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Clinical Trial Updates Glutamate Modulation
PRESS RELEASE

published on 09/05/2025 at 07:00, 4 months 28 days ago

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
Newron Pharmaceuticals to present data on evenamide as add-on treatment for schizophrenia at 2025 WCBP. Focus on efficacy, safety, and mechanism of action. Landmark studies showcased

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide WCBP
BRIEF

published on 08/12/2025 at 07:05, 5 months 22 days ago

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
PRESS RELEASE

published on 08/12/2025 at 07:00, 5 months 22 days ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 08/11/2025 at 07:05, 5 months 23 days ago

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
PRESS RELEASE

published on 08/11/2025 at 07:00, 5 months 23 days ago

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus
BRIEF

published on 05/12/2025 at 07:05, 8 months 22 days ago

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
PRESS RELEASE

published on 05/12/2025 at 07:00, 8 months 22 days ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program

Accesswire

Published on 02/03/2026 at 11:30, 14 minutes ago

Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner
Published on 02/03/2026 at 09:01, 2 hours 43 minutes ago

Star Copper Completes Copperline Field Program with Drill Permit Submitted for 2026
Published on 02/02/2026 at 23:55, 11 hours 49 minutes ago

2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 11 hours 49 minutes ago

55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 12 hours 19 minutes ago

Western Announces Sale of GlassMasters Investment

View all ACCESSWIRE

EQS Group

Published on 02/03/2026 at 11:15, 28 minutes ago

EQS-Adhoc: hGears AG Group: Preliminary revenue and adjusted EBITDA for 2025 slightly above Management’s guidance; free cash flow affected by reclassification effect
Published on 02/03/2026 at 11:05, 38 minutes ago

2026 International AI Safety Report Charts Rapid Changes and Emerging Risks
Published on 02/03/2026 at 10:05, 1 hour 38 minutes ago

Home and Kitchenware Brand Karaca Expands in Germany
Published on 02/03/2026 at 10:05, 1 hour 38 minutes ago

Hisense Named World's First Customer Centricity Lighthouse Factory in the TV Industry by World Economic Forum
Published on 02/03/2026 at 09:40, 2 hours 3 minutes ago

Lemon Learning Acquires Aidaxis to Expand Desktop Application Coverage

Les Echos

Published on 02/03/2026 at 08:00, 3 hours 44 minutes ago

EURAZEO & PANTHEON ESTABLISH A NEARLY €500 MILLION PRIVATE DEBT CONTINUATION VEHICLE
Published on 02/03/2026 at 08:00, 3 hours 44 minutes ago

Neoen launches three new solar farms in France with a total capacity of 230 MWp
Published on 02/02/2026 at 18:23, 17 hours 20 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:00, 17 hours 44 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 17:35, 18 hours 9 minutes ago

Disclosure of transactions in own shares from January 26 to January 30, 2026

View all LES ECHOS COMFI WIRE